Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Holdings

2,320.68
-15.6487-0.67%
Number of Gainers:21
Number of Losers:75
Number of Flat:1
PE:- -
High:2,338.96
Open:2,336.60
Low:2,316.52
Close:2,336.33
Volume:1.23B
Turnover:266.58B
Market Cap:51.47T
Float Cap:48.16T

Loading ...

Analysts Offer Insights on Consumer Goods Companies: Walmart (WMT) and Mama’s Creations (MAMA)

TIPRANKS
·
Sep 08

ADP Expands Strategic Partnership with AWS to Accelerate AI-Powered HCM Innovation

Reuters
·
Sep 08

Verizon, Corning enter multi-billion dollar agreement for 80M miles of fiber

TIPRANKS
·
Sep 08

Qualcomm Stock Jumps 8% Thanks to Deal with Amazon

Dow Jones
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and MiMedx Group (MDXG)

TIPRANKS
·
Sep 08

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

GlobeNewswire
·
Sep 08

Qualcomm to issue warrant to Amazon.com for up to 25M shares

TIPRANKS
·
Sep 08

Amazon and AT&T Team up to Challenge SpaceX's Satellite Dominance

Dow Jones
·
Sep 08

Mediacom Names Anthony Bowling Senior Vice President, Field Operations Strategy and Operational Excellence

Reuters
·
Sep 08

Accenture, Google Cloud launch Accenture Gemini Enterprise Business Group

TIPRANKS
·
Sep 08

Qualcomm Shares up 10.1% Premarket After Co, Amazon to Develop Custom Chips for AI Data Centers

THOMSON REUTERS
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Qualcomm announces multi-generation collaboration with Amazon.com

TIPRANKS
·
Sep 08

Qualcomm Partners with Amazon on Multi-Generation Custom Chips for AWS AI Data Centers

Reuters
·
Sep 08

LIVE Markets-the Factor Derby is Down to Two Horses

Reuters
·
Sep 08

Sector Update: Healthcare

MT Newswires Live
·
Sep 08

Notable open interest changes for September 8th

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08